Connor, Clark & Lunn Investment Management (CC&L)’s Meridian Bioscience Inc VIVO Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-15,571	Closed	-$363K	–	1175
2020 Q2	$363K	Sell	15,571 -87,329	-85%	-$1.27M	﹤0.01%	812
2020 Q1	$864K	Buy	102,900 +36,200	+54%	+$305K	0.01%	589
2019 Q4	$652K	Sell	66,700 -38,575	-37%	-$362K	﹤0.01%	617
2019 Q3	$999K	Buy	105,275 +22,750	+28%	+$240K	0.01%	546
2019 Q2	$980K	Buy	+82,525	New	+$994K	0.01%	573
2019 Q1	–	Sell	-22,850	Closed	-$397K	–	1072
2018 Q4	$397K	Sell	22,850 -72,900	-76%	-$1.24M	﹤0.01%	748
2018 Q3	$1.43M	Buy	95,750 +27,425	+40%	+$425K	0.01%	503
2018 Q2	$1.09M	Buy	68,325 +23,425	+52%	+$349K	0.01%	596
2018 Q1	$638K	Buy	44,900 +18,300	+69%	+$271K	﹤0.01%	537
2017 Q4	$372K	Buy	26,600 +10,225	+62%	+$150K	﹤0.01%	659
2017 Q3	$234K	Buy	+16,375	New	+$234K	﹤0.01%	735

Other funds holding VIVO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Prudential Financial Newark, New Jersey $91.8B AUM 38.24% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s VIVO Position: Q3 2020 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Meridian Bioscience Inc (VIVO) in Q3 2020, closing a stake of 15,571 shares — an estimated $363K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in VIVO in Q3 2017 and held it in 11 quarters. The position peaked at $1.43M in Q3 2018. 191 funds tracked by Wall St. Rank hold VIVO as of Q3 2020.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Meridian Bioscience Inc position as of Q3 2020 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 15,571 Meridian Bioscience Inc shares in Q3 2020, an estimated $363K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Meridian Bioscience Inc in Q3 2017 and held it in 11 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Meridian Bioscience Inc position peaked at $1.43M in Q3 2018.
191 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q3 2020.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q3 2020, filed 12 Nov 2020.